Access Industries and Len Blavatnik Disclose 10.4% Stake in Hemab Therapeutics Post-IPO
COAG is trading near its 52-week low of $23 (8.7% above the low).
Summary
Access Industries and Len Blavatnik have become a major shareholder in Hemab Therapeutics, acquiring a 10.4% stake, including a $19.8 million direct investment in the company's recent IPO at $18.00 per share.
Key Events · Ownership and Investor Activity · COAG
-
New 10.4% Beneficial Ownership
AI DEN-MAB LLC and affiliated entities, including Len Blavatnik, reported beneficial ownership of 4,876,344 shares, representing 10.4% of Hemab Therapeutics Holdings, Inc. common stock following the company's IPO on May 4, 2026.
-
Significant IPO Investment
The reporting group purchased 1,100,000 shares directly in the company's initial public offering at the public offering price of $18.00 per share, totaling $19.8 million. This was part of the IPO completed on May 4, 2026.
-
Lock-Up and Investor Rights Agreements
The reporting persons are subject to a 180-day lock-up agreement from April 30, 2026, restricting share sales, and hold customary demand and piggyback registration rights exercisable after this period.
Analysis · COAG · Life Sciences
Access Industries, led by Len Blavatnik, has disclosed a significant 10.4% beneficial ownership stake in Hemab Therapeutics Holdings, Inc. following its recent initial public offering. This includes a direct purchase of 1.1 million shares in the IPO at $18.00 per share, demonstrating substantial institutional confidence in the company's prospects shortly after its market debut. This investment, made at a price below the current market value, signals strong conviction from a major investor.
At the time of this filing, COAG was trading at $25.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $23.00 to $32.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.